These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 9779762

  • 1. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
    Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH, Connor E.
    Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
    [Abstract] [Full Text] [Related]

  • 2. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
    Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Carlin D, Connor E.
    Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
    [Abstract] [Full Text] [Related]

  • 3. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.
    Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EA, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA.
    Antimicrob Agents Chemother; 1999 May; 43(5):1183-8. PubMed ID: 10223933
    [Abstract] [Full Text] [Related]

  • 4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 5. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.
    Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH, Connor EM, MEDI-493 Study Group.
    Pediatr Infect Dis J; 2004 Aug; 23(8):707-12. PubMed ID: 15295219
    [Abstract] [Full Text] [Related]

  • 6. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C, Scott LJ, Plosker GL.
    Paediatr Drugs; 2004 Aug; 6(3):177-97. PubMed ID: 15170364
    [Abstract] [Full Text] [Related]

  • 7. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group.
    BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274
    [Abstract] [Full Text] [Related]

  • 8. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov 03; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 9. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P, Composs Investigators.
    Pediatr Infect Dis J; 2002 Jun 03; 21(6):512-8. PubMed ID: 12182374
    [Abstract] [Full Text] [Related]

  • 10. Palivizumab use in very premature infants in the neonatal intensive care unit.
    Wu SY, Bonaparte J, Pyati S.
    Pediatrics; 2004 Nov 03; 114(5):e554-6. PubMed ID: 15520088
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.
    J Manag Care Pharm; 2010 Nov 03; 16(1):46-58. PubMed ID: 20131495
    [Abstract] [Full Text] [Related]

  • 15. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
    Pediatrics; 1997 Jan 03; 99(1):93-9. PubMed ID: 8989345
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
    Null D, Pollara B, Dennehy PH, Steichen J, Sánchez PJ, Givner LB, Carlin D, Landry B, Top FH, Connor E.
    Pediatr Infect Dis J; 2005 Nov 03; 24(11):1021-3. PubMed ID: 16282947
    [Abstract] [Full Text] [Related]

  • 17. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014 Nov 03; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 03; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 20. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
    Aliamovskaia GA, Keshinian ES.
    Vestn Ross Akad Med Nauk; 2012 Dec 03; (12):30, 32-4. PubMed ID: 23530423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.